HOME 2022-12-01T20:34:06+00:00

Over 10 million people worldwide are living with Parkinson’s disease (PD) or related disorders such as progressive supranuclear palsy (PSP).  These diseases are characterized by relentlessly worsening motor and cognitive function, caused by degeneration of nerve cells in the brain.  No currently available medication slows or arrests disease progression.  Even symptomatic treatments show declining usefulness in advanced PD and are often ineffective in PSP.  There is an urgent and unmet need for effective treatments for these diseases.

Our work is focused on understanding the mechanisms underlying neurodegeneration in PD and PSP, as an essential step towards developing effective treatments.   Our current projects focus on the roles of the proteins α-Synuclein and Tau in the populations of brain neurons that selectively degenerate in these diseases.  To understand how accumulation of α-Synuclein and Tau causes neurodegeneration, we use a variety of different experimental models and approaches, including engineered viral vectors that alter gene expression in the rodent brain, and transgenic zebrafish that can be analyzed by intravital microscopy, electrophysiology, genetics and biochemistry.  We are also carrying out unbiased phenotype-based chemical modifier screens in zebrafish models for drug discovery.  The ultimate goal of our work is to develop treatments that prevent disease progression and thereby improve patients’ prognosis and quality of life.

News:

11/1/2022 Darius’ paper “Quantification of functional recovery in a larval zebrafish model of spinal cord injury” features on the cover of the The Journal of Neuroscience Research
10/27/2022 Ed presented our work on drug discovery for PSP at Portland VA PADRECC and OHSU Parkinson’s disease center.
7/8/2022 Our work on generating and detecting ROS in dopaminergic neurons of transgenic zebrafish to understand PD pathophysiology featured in Parkinson’s News Today.
1/1/2022 Our new collaborative NINDS R61/R33 grant on balance in zebrafish PSP models with David Schoppik at NYU starts today.
10/01/2021 Our new VA I01 grant on molecular mechanisms of neuroinflammation in PSP starts today.
07/19/2021 Harry’s paper “Sinusoidal analysis reveals a non-linear and dopamine-dependent relationship between ambient illumination and motor activity in larval zebrafish” published in Neuroscience Letters.
07/01/2021 Our new NINDS R21 grant on genetic modifiers of PSP starts today.
04/28/2021 Darius awarded a Dean’s Fellowship to work on drug discovery for tauopathy using zebrafish models.
03/17/2021  Vlad’s paper “Mechanism of pacemaker activity in zebrafish DC2/4 dopaminergic neurons” published in The Journal of Neuroscience.